GE Medical Systems has acquired German ultrasound vendor KranzbuhlerMedizinische Systeme (KMS), a Solingen-based firm that has beenworking closely with the Milwaukee vendor since 1994. KMS employs93 people and had revenues of DM62 million ($40.6 million)
GE Medical Systems has acquired German ultrasound vendor KranzbuhlerMedizinische Systeme (KMS), a Solingen-based firm that has beenworking closely with the Milwaukee vendor since 1994. KMS employs93 people and had revenues of DM62 million ($40.6 million) lastyear.
KMS claims a considerable market share in Europe for color Dopplerultrasound systems, and helped GE with the launch of the Logiq500 scanner. Some 73% of KMS revenues are derived from ultrasoundsales, with the rest coming from monitors for cardiotocographicanalysis as well as patient data management systems for hospitalmaternity wards.
In other GE international news, the company formed a joint venturewith a Chinese partner for manufacturing and marketing of ultrasoundequipment in China. GE Haiying Medical Systems will be based inWuxi, Jiangsu province, and is a partnership between GEMS andthe China State Shipbuilding Corporation.
GE Haiying is the third joint venture between GEMS and a Chinesepartner. Other joint ventures include GE Hangwei Medical Systems,for the manufacture of CT scanners, and a joint venture establishedin March to manufacture x-ray equipment.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.